Rapport Therapeutics, Inc.
RAPP
$27.62
-$0.22-0.79%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 37.03% | 51.02% | 82.36% | 118.38% | 170.42% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 50.62% | 48.14% | 63.47% | 93.56% | 129.57% |
| Operating Income | -50.62% | -48.14% | -63.47% | -93.56% | -129.57% |
| Income Before Tax | -42.37% | -36.00% | -40.15% | -55.37% | -125.18% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -42.37% | -35.99% | -40.14% | -55.34% | -125.11% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -42.37% | -35.99% | -40.14% | -55.34% | -125.11% |
| EBIT | -50.62% | -48.14% | -63.47% | -93.56% | -129.57% |
| EBITDA | -50.92% | -48.04% | -63.05% | -92.62% | -127.95% |
| EPS Basic | 79.31% | 87.24% | 90.52% | 88.18% | 38.90% |
| Normalized Basic EPS | 72.01% | 84.58% | 88.99% | 86.48% | 53.14% |
| EPS Diluted | 79.31% | 87.24% | 90.52% | 88.18% | 38.90% |
| Normalized Diluted EPS | 72.01% | 84.58% | 88.99% | 86.48% | 53.14% |
| Average Basic Shares Outstanding | 88.31% | 191.75% | 782.75% | 1,627.86% | 1,272.44% |
| Average Diluted Shares Outstanding | 88.31% | 191.75% | 782.75% | 1,627.86% | 1,272.44% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |